JP2020073546A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020073546A5 JP2020073546A5 JP2019237753A JP2019237753A JP2020073546A5 JP 2020073546 A5 JP2020073546 A5 JP 2020073546A5 JP 2019237753 A JP2019237753 A JP 2019237753A JP 2019237753 A JP2019237753 A JP 2019237753A JP 2020073546 A5 JP2020073546 A5 JP 2020073546A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- diseases
- pharmaceutical composition
- active organic
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 17
- 201000010099 disease Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 208000019423 liver disease Diseases 0.000 claims 6
- 150000007524 organic acids Chemical class 0.000 claims 5
- 235000005985 organic acids Nutrition 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 229940093265 berberine Drugs 0.000 claims 4
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims 4
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 208000019622 heart disease Diseases 0.000 claims 3
- 208000030159 metabolic disease Diseases 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- 150000007530 organic bases Chemical class 0.000 claims 2
- 208000001076 sarcopenia Diseases 0.000 claims 2
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims 2
- 229960001661 ursodiol Drugs 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- 229930003779 Vitamin B12 Natural products 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 229960002873 benfotiamine Drugs 0.000 claims 1
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 claims 1
- 150000003836 berberines Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 230000007870 cholestasis Effects 0.000 claims 1
- 231100000359 cholestasis Toxicity 0.000 claims 1
- 229940046374 chromium picolinate Drugs 0.000 claims 1
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000000284 extract Substances 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 229910052720 vanadium Inorganic materials 0.000 claims 1
- 229940045605 vanadium Drugs 0.000 claims 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 235000019163 vitamin B12 Nutrition 0.000 claims 1
- 239000011715 vitamin B12 Substances 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 239000011718 vitamin C Substances 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021190958A JP7285903B2 (ja) | 2014-07-29 | 2021-11-25 | ベルベリン塩、ウルソデオキシコール酸塩ならびに組み合わせ、その調製および適用方法 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462030147P | 2014-07-29 | 2014-07-29 | |
| US201462030140P | 2014-07-29 | 2014-07-29 | |
| US62/030,140 | 2014-07-29 | ||
| US62/030,147 | 2014-07-29 | ||
| US201562128077P | 2015-03-04 | 2015-03-04 | |
| US62/128,077 | 2015-03-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016564633A Division JP6917144B2 (ja) | 2014-07-29 | 2015-07-28 | ベルベリン塩、ウルソデオキシコール酸塩ならびに組み合わせ、その調製および適用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021190958A Division JP7285903B2 (ja) | 2014-07-29 | 2021-11-25 | ベルベリン塩、ウルソデオキシコール酸塩ならびに組み合わせ、その調製および適用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020073546A JP2020073546A (ja) | 2020-05-14 |
| JP2020073546A5 true JP2020073546A5 (enExample) | 2020-10-08 |
Family
ID=55216773
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016564633A Active JP6917144B2 (ja) | 2014-07-29 | 2015-07-28 | ベルベリン塩、ウルソデオキシコール酸塩ならびに組み合わせ、その調製および適用方法 |
| JP2019237753A Pending JP2020073546A (ja) | 2014-07-29 | 2019-12-27 | ベルベリン塩、ウルソデオキシコール酸塩ならびに組み合わせ、その調製および適用方法 |
| JP2021190958A Active JP7285903B2 (ja) | 2014-07-29 | 2021-11-25 | ベルベリン塩、ウルソデオキシコール酸塩ならびに組み合わせ、その調製および適用方法 |
| JP2023084632A Pending JP2023099689A (ja) | 2014-07-29 | 2023-05-23 | ベルベリン塩、ウルソデオキシコール酸塩ならびに組み合わせ、その調製および適用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016564633A Active JP6917144B2 (ja) | 2014-07-29 | 2015-07-28 | ベルベリン塩、ウルソデオキシコール酸塩ならびに組み合わせ、その調製および適用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021190958A Active JP7285903B2 (ja) | 2014-07-29 | 2021-11-25 | ベルベリン塩、ウルソデオキシコール酸塩ならびに組み合わせ、その調製および適用方法 |
| JP2023084632A Pending JP2023099689A (ja) | 2014-07-29 | 2023-05-23 | ベルベリン塩、ウルソデオキシコール酸塩ならびに組み合わせ、その調製および適用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10301303B2 (enExample) |
| EP (1) | EP3174874B1 (enExample) |
| JP (4) | JP6917144B2 (enExample) |
| KR (3) | KR102573865B1 (enExample) |
| CN (2) | CN106687460B (enExample) |
| AU (2) | AU2015296098B2 (enExample) |
| BR (1) | BR112017001623B1 (enExample) |
| CA (2) | CA2945609C (enExample) |
| DK (1) | DK3174874T3 (enExample) |
| EA (1) | EA032971B1 (enExample) |
| ES (1) | ES2835874T3 (enExample) |
| IL (3) | IL294063B2 (enExample) |
| MX (3) | MX373840B (enExample) |
| NZ (1) | NZ728488A (enExample) |
| SG (1) | SG11201700481YA (enExample) |
| WO (1) | WO2016015634A1 (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| EP3139910B1 (en) | 2014-05-05 | 2019-11-27 | The Board of Regents of The University of Texas System | Compositions comprising ursolic acid and/or resveratrol for treating obesity |
| WO2015183794A1 (en) * | 2014-05-27 | 2015-12-03 | City Of Hope | Tgr5 agonist complexes for treating diabetes and cancer |
| EP3149156B1 (en) | 2014-05-28 | 2021-02-17 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
| NZ728488A (en) * | 2014-07-29 | 2023-03-31 | Shenzhen Hightide Biopharmaceutical Ltd | Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof |
| JP6804438B2 (ja) | 2014-10-17 | 2020-12-23 | チルドレンズ ホスピタル メディカル センター | 多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法 |
| US20180050048A1 (en) * | 2015-04-06 | 2018-02-22 | SHENZHEN HJGHTIDE-BIOPHARMAGEUTiCAL, LTD. | Conjugate compounds of ursodeoxycholic, berberine or l-carnitine, and compositions and methods thereof |
| US12137716B2 (en) | 2015-04-16 | 2024-11-12 | Michael Hudnall | Methods of liver disease treatment |
| CN105168228B (zh) * | 2015-11-04 | 2016-06-22 | 北京凯因科技股份有限公司 | 奥贝胆酸和小檗碱的复方组合物及其应用 |
| CN106692973A (zh) * | 2015-11-13 | 2017-05-24 | 深圳君圣泰生物技术有限公司 | 一种组合物及其用途、药物制剂 |
| CN105693805A (zh) * | 2016-03-15 | 2016-06-22 | 合肥华方医药科技有限公司 | 一种胆酸类小檗碱偶合物的制备及医药用途 |
| CN105801663A (zh) * | 2016-03-15 | 2016-07-27 | 合肥华方医药科技有限公司 | 一种熊果酸小檗碱偶合物的制备方法及医药用途 |
| GB201605013D0 (en) * | 2016-03-24 | 2016-05-11 | Inst Of Food Res | S-methylcysteine sulfoxide for prostate cancer treatment |
| ITUA20163025A1 (it) | 2016-04-29 | 2017-10-29 | Sochim Int S P A | Composizione per il trattamento della sindrome dell’ovaio policistico |
| EP4177335A1 (en) | 2016-05-05 | 2023-05-10 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
| CA3023648C (en) * | 2016-05-10 | 2023-11-28 | Shenzhen Hightide Biopharmaceutical, Ltd. | Pharmaceutical composition of berberine with epa and dha |
| WO2017218004A1 (en) * | 2016-06-17 | 2017-12-21 | Michael Hudnall | Medical food for patients with chronic liver disease |
| CN105963306B (zh) * | 2016-07-05 | 2018-08-17 | 福州大学 | 一种具有协同抗肿瘤转移活性的药物组合物 |
| US10729735B1 (en) | 2016-09-14 | 2020-08-04 | Phoenix Biotechnology, Inc. | Method and compostitions for treating coronavirus infection |
| US10596186B2 (en) | 2016-09-14 | 2020-03-24 | Phoenix Biotechnology, Inc. | Method and compositions for treating viral infections |
| EP3512524B1 (en) * | 2016-09-14 | 2021-04-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating viral infection |
| US10702567B2 (en) | 2016-09-14 | 2020-07-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating viral infection |
| US10703761B2 (en) * | 2016-10-18 | 2020-07-07 | City Of Hope | Bile acid receptor modulators and methods of use thereof |
| EP3534976A4 (en) | 2016-11-04 | 2020-09-16 | Children's Hospital Medical Center | PATHOLOGICAL MODELS OF HEPATIC ORGANOIDS AND ASSOCIATED METHODS OF MANUFACTURE AND USE |
| EP3548507A4 (en) | 2016-12-05 | 2020-07-15 | Children's Hospital Medical Center | COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF |
| US10471007B2 (en) * | 2016-12-16 | 2019-11-12 | Jeffrey R Olynyk | Sublingual therapeutic solutions and methods |
| IT201700032960A1 (it) | 2017-03-24 | 2018-09-24 | Akademy Pharma S R L | Composto nutraceutico per il trattamento dell’eccesso di peso e della moderata ipercolesterolemia e disglicemia |
| US20230404107A1 (en) * | 2017-03-28 | 2023-12-21 | IRP Health Pty Ltd | Berberine alkaloids in the prevention and/or treatment of intestinal disease |
| EP3609997A4 (en) | 2017-04-14 | 2021-03-03 | Children's Hospital Medical Center | COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES |
| IL270162B2 (en) * | 2017-04-25 | 2025-07-01 | Buck Inst Res Aging | ?-ketoglutarate (akg) and (i) a vitamin a compound, or (ii) a vitamin d compound, for use in delaying onset or delaying progression of frailty |
| CN108864077B (zh) * | 2017-05-12 | 2020-05-22 | 深圳君圣泰生物技术有限公司 | 小檗碱有机酸盐的固体形式及其制备方法 |
| WO2019023245A1 (en) * | 2017-07-25 | 2019-01-31 | Cedars-Sinai Medical Center | METHODS OF TREATING HEPATIC DISEASES |
| CN111295203B (zh) * | 2017-08-11 | 2022-09-06 | 深圳君圣泰生物技术有限公司 | 用于治疗炎症性肠病的方法和组合物 |
| EP3694603A4 (en) | 2017-10-10 | 2021-07-14 | Children's Hospital Medical Center | ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF |
| JP2021504546A (ja) * | 2017-11-29 | 2021-02-15 | ビーエイエスエフ・ソシエタス・エウロパエアＢａｓｆ Ｓｅ | 組成物、その製造方法および使用方法 |
| US12379372B2 (en) | 2017-12-21 | 2025-08-05 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| CN112543635A (zh) | 2018-05-29 | 2021-03-23 | Irp健康股份有限公司 | 硝基咪唑制剂 |
| KR102887406B1 (ko) | 2018-07-26 | 2025-11-19 | 칠드런즈 호스피탈 메디칼 센터 | 간-담도-췌장 조직 및 이를 제조하는 방법 |
| WO2020056158A1 (en) | 2018-09-12 | 2020-03-19 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| IL281761B2 (en) | 2018-09-25 | 2025-09-01 | Ponce De Leon Health Designated Activity Company | Process for preparing calcium alpha-ketoglutarate |
| CN109303921B (zh) * | 2018-10-30 | 2021-02-09 | 中国药科大学 | Fxr激动剂与sirt1激动剂联用在制备抗肝纤维化药物中的应用 |
| IT201800011155A1 (it) * | 2018-12-17 | 2020-06-17 | S&R Farm S P A | uso di una miscela di berberina e resveratrolo per il controllo delle dislipidemie |
| CN111499626A (zh) * | 2019-01-31 | 2020-08-07 | 西南大学 | 一种表小檗碱的合成方法及应用 |
| CN109999034A (zh) * | 2019-02-11 | 2019-07-12 | 浙江理工大学 | 肿瘤蛋白tnik激酶靶向天然小分子抑制剂及其应用 |
| JP7598591B2 (ja) * | 2019-03-01 | 2024-12-12 | 慶應義塾 | Ｈｉｆ抑制用組成物 |
| CN109806264B (zh) * | 2019-04-10 | 2021-04-02 | 江苏海钥医药科技有限公司 | 药物组合物及其应用 |
| CN112076199A (zh) * | 2019-06-13 | 2020-12-15 | 谢亚坚 | 一种降血糖降血脂和降血胆固醇方剂 |
| CN110368392A (zh) * | 2019-08-20 | 2019-10-25 | 延边大学 | 科罗索酸在制备抗肝损伤药物或抗肝损伤保健品中的应用 |
| CN112851660B (zh) * | 2019-11-12 | 2022-03-18 | 广东药科大学 | 含有小檗碱的酸-碱加成盐、其制备方法及其作为药物的用途 |
| CN111116578B (zh) * | 2019-12-26 | 2021-06-04 | 深圳市老年医学研究所 | 去亚甲基小檗碱的制备方法及其应用 |
| KR102150821B1 (ko) * | 2020-01-22 | 2020-09-03 | 주식회사 에이스바이오메드 | 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제 |
| US11806359B2 (en) | 2020-03-31 | 2023-11-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating Coronavirus infection |
| US20230181547A1 (en) * | 2020-05-15 | 2023-06-15 | Nguyen Anh VAN | Solid lipid nano-composition containing berberine and cinnamonaldehyde effective in treating diabetes, dyslipidemia, and method of preparing the same |
| US11957649B2 (en) | 2020-06-02 | 2024-04-16 | Glykon Technologies Group, Llc | Methods and pharmaceutical preparations for elevating ketone utilization |
| JP7741169B2 (ja) * | 2020-08-12 | 2025-09-17 | アーチャー－ダニエルズ－ミッドランド カンパニー | ２，５－フランジカルボン酸ジメチルエステル、及びその他のエステル化生成物の精製 |
| CN114195850B (zh) * | 2020-09-18 | 2024-08-16 | 成都贝诺科成生物科技有限公司 | 一种用于防治肝病的化合物及其制药用途 |
| KR102636847B1 (ko) * | 2020-09-18 | 2024-02-19 | 경북대학교 산학협력단 | 티아민 유도체를 포함하는 이식편대숙주질환 예방 또는 치료용 약학적 조성물 |
| WO2022083713A1 (en) * | 2020-10-23 | 2022-04-28 | Shenzhen Hightide Biopharmaceutical Ltd. | Compositions of berberine ursodeoxycholate and methods thereof for treating fatty liver disease, diabetes and hyperlipidemia |
| WO2022161468A1 (en) * | 2021-01-28 | 2022-08-04 | Shenzhen Hightide Biopharmaceutical Ltd. | Compositions of berberine ursodeoxycholate and methods thereof for treating primary sclerosing cholangitis |
| CN113143962B (zh) * | 2021-05-11 | 2022-08-05 | 四川九章生物科技有限公司 | 一种治疗高脂血症的药物组合物及其制备方法 |
| WO2023027994A1 (en) * | 2021-08-23 | 2023-03-02 | Paxmedica, Inc. | Methods for treating nervous system disorders with antipurinergic agents |
| CN113577064B (zh) * | 2021-09-09 | 2023-07-04 | 浙江中医药大学 | 一种增强肿瘤免疫的联合用药物组合物及其应用 |
| JPWO2023074894A1 (enExample) * | 2021-11-01 | 2023-05-04 | ||
| WO2023091173A1 (en) * | 2021-11-16 | 2023-05-25 | Michael Hudnall | Methods of liver disease treatment |
| WO2023088463A1 (en) * | 2021-11-22 | 2023-05-25 | Shenzhen Hightide Biopharmaceutical Ltd. | Compositions and methods of berberine ursodeoxycholate for modulating gut microbiome compositions |
| CN116178384A (zh) * | 2021-11-29 | 2023-05-30 | 湖南师范大学 | 四种小檗碱中短链脂肪酸盐的制备 |
| CN114716498B (zh) * | 2022-01-20 | 2024-01-23 | 成都贝诺科成生物科技有限公司 | 一种高稳定性的失碳熊去氧胆酸小檗碱盐晶型及其制备方法 |
| KR20230156533A (ko) * | 2022-05-06 | 2023-11-14 | 동아대학교 산학협력단 | 이소퀴놀린 유도체 화합물을 유효성분으로 포함하는 미토파지 활성 촉진용 조성물 및 이의 용도 |
| EP4547256A1 (en) * | 2022-07-01 | 2025-05-07 | Intercept Pharmaceuticals, Inc. | Methods for ameliorating cognitive impairment using bile acid derivatives |
| CN115011661B (zh) * | 2022-07-22 | 2024-06-21 | 湖南科瑞生物制药股份有限公司 | 一种3β-熊去氧胆酸的合成方法 |
| KR102828609B1 (ko) * | 2022-10-11 | 2025-07-02 | 주식회사 알트메디칼 | 이소퀴놀린 유도체를 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 조성물 |
| KR20240052403A (ko) * | 2022-10-14 | 2024-04-23 | 주식회사 알트메디칼 | 이소퀴놀린 유도체를 유효성분으로 포함하는 말초신경병증의 예방 또는 치료용 조성물 |
| KR20240054685A (ko) * | 2022-10-19 | 2024-04-26 | 주식회사 알트메디칼 | 이소퀴놀린 유도체를 유효성분으로 포함하는 멜라스증후군의 예방 또는 치료용 조성물 |
| WO2024120452A1 (en) * | 2022-12-07 | 2024-06-13 | Shenzhen Hightide Biopharmaceutical Ltd. | Compositions and methods for prophylaxis and treatment of covid-19 |
| EP4642454A1 (en) * | 2022-12-30 | 2025-11-05 | Shenzhen Hightide Biopharmaceutical Ltd. | Pharmaceutical combinations and compositions, and methods of use thereof |
| KR20250166895A (ko) * | 2023-02-15 | 2025-11-28 | 센젠 하이타이드 바이오파마슈티컬 리미티드 | 베르베린 타우로우르소데옥시콜레이트 조성물 및 이의 방법 |
| WO2024179570A1 (en) * | 2023-03-01 | 2024-09-06 | Shenzhen Hightide Biopharmaceutical Ltd. | Compositions and methods for treating severe hypertriglyceridemia |
| WO2024222408A1 (zh) * | 2023-04-28 | 2024-10-31 | 杭州居维叶生物医药有限公司 | 一种黄连素维生素c盐组合物、制备方法及其应用 |
| WO2024245370A1 (zh) * | 2023-05-31 | 2024-12-05 | 上海复宏汉霖生物技术股份有限公司 | 一种组合产品、盐及其用途 |
| WO2024245371A1 (zh) * | 2023-05-31 | 2024-12-05 | 上海复宏汉霖生物技术股份有限公司 | 一种组合产品、盐及其用于治疗神经退行性疾病或病症的用途 |
| CN116850186A (zh) * | 2023-06-02 | 2023-10-10 | 深圳市第二人民医院(深圳市转化医学研究院) | 一种多靶点神经元保护剂在防治神经系统退行性疾病中的应用 |
| WO2025053283A1 (ja) * | 2023-09-07 | 2025-03-13 | 株式会社マイトジェニック | ベルベルビン関連化合物 |
| CN117398395B (zh) * | 2023-12-14 | 2024-02-09 | 成都贝诺科成生物科技有限公司 | 失碳熊去氧胆酸小檗碱盐在制备预防和/或治疗消化道炎症的药物中的用途 |
| WO2025130826A1 (en) * | 2023-12-18 | 2025-06-26 | Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences | Compositions and methods for treating cancer |
| KR20250116419A (ko) * | 2024-01-25 | 2025-08-01 | 주식회사 알트메디칼 | 이소퀴놀린 유도체 화합물을 유효성분으로 포함하는 당뇨병성 신증의 예방 또는 치료용 약학적 조성물 |
| CN120267634A (zh) * | 2025-04-09 | 2025-07-08 | 中国药科大学 | 一种外泌体融合肝靶向脂质体递药系统及其制备方法和应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5529075B2 (enExample) * | 1971-08-20 | 1980-07-31 | ||
| IT1136624B (it) | 1981-05-21 | 1986-09-03 | Erregierre Ind Chim Spa | Prodotti di salificazione di acidi colici,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo |
| JPS60163897A (ja) | 1984-02-06 | 1985-08-26 | Tokyo Tanabe Co Ltd | ウルソデオキシコ−ル酸メグルミン塩およびその注射剤 |
| JPS6256192A (ja) | 1985-09-06 | 1987-03-11 | Hitachi Ltd | 感熱転写材 |
| IT1245889B (it) | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche per uso orale gastroresistenti contenenti sali di acidi biliari. |
| JPH06256192A (ja) | 1993-03-05 | 1994-09-13 | Nitsusui Seiyaku Kk | 液状薬剤の製造法 |
| FR2796551B1 (fr) * | 1999-07-23 | 2003-07-25 | Lipha | Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant |
| KR20050081477A (ko) | 2004-02-13 | 2005-08-19 | 켐젠주식회사 | 암로디핀 담즙산염, 그의 제조방법 및 이를 함유하는경구투여용 약학 조성물 |
| CN1759834B (zh) | 2004-09-17 | 2010-06-23 | 中国医学科学院医药生物技术研究所 | 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途 |
| CN1762367A (zh) | 2004-10-18 | 2006-04-26 | 孙民富 | 熊去氧胆酸滴丸的处方及其制作方法 |
| US20070032555A1 (en) | 2005-07-01 | 2007-02-08 | Concert Pharmaceuticals Inc. | Novel aryloxyphenyl-propanamines |
| WO2007005644A2 (en) | 2005-07-01 | 2007-01-11 | Concert Pharmaceuticals Inc. | Novel aryloxypropanamines |
| JP2009502961A (ja) | 2005-07-29 | 2009-01-29 | コンサート ファーマシューティカルズ インコーポレイテッド | 新規な医薬組成物 |
| JP5301991B2 (ja) | 2005-07-29 | 2013-09-25 | コンサート ファーマシューティカルズ インコーポレイテッド | 新規なベンゾ［ｄ］［１，３］−ジオキソール誘導体 |
| CA2640414C (en) * | 2006-02-09 | 2013-07-09 | National Research Council Of Canada | Combinations of botanical extracts for promoting cardiovascular health |
| CN100509840C (zh) | 2006-05-10 | 2009-07-08 | 华中科技大学 | 浙贝乙素和胆汁酸的衍生物及药物组合物 |
| CN101113149B (zh) * | 2006-07-25 | 2011-04-27 | 复旦大学 | 小檗碱类生物碱的脂肪族有机酸盐及其制备方法和应用 |
| EP2116612B1 (en) * | 2007-02-28 | 2017-08-30 | DENKA SEIKEN Co., Ltd. | Reagent for determination of quantity of small dense low-density lipoprotein |
| AU2008299921B2 (en) * | 2007-09-13 | 2012-03-01 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof |
| CA2723132C (en) | 2008-05-01 | 2014-04-08 | Afexa Life Sciences Inc. | Pharmaceutical composition comprising extracts of huanglian and ku ding cha effective for lowering blood lipid levels |
| IT1393095B1 (it) * | 2009-02-19 | 2012-04-11 | Prodotti Chimici Alimentari | Processo per la sintesi del sale disodico dell'acido ursodesossicolico 3,7-disolfato. |
| RU2011139643A (ru) * | 2009-03-17 | 2013-04-27 | Акскан Фарма, Инк. | Способ лечения неалкогольного стеатогепатита повышенными дозами урсодезоксихолевой кислоты |
| JP2010246578A (ja) * | 2009-04-10 | 2010-11-04 | Utsunomiya Univ | 血中コレステロールの検査方法および検査装置 |
| US20100323031A1 (en) * | 2009-06-22 | 2010-12-23 | Glykon Technologies Group, Llc | Synergistic combination to enhance blood glucose and insulin metabolism |
| CN101987860B (zh) * | 2009-08-06 | 2011-12-14 | 中山百灵生物技术有限公司 | 一种熊去氧胆酸的制备方法 |
| CN101879162A (zh) * | 2010-02-23 | 2010-11-10 | 江苏格林生物科技有限公司 | 一种α-亚麻酸乙酯配伍小檗碱的减肥物 |
| CN102869382A (zh) * | 2010-06-10 | 2013-01-09 | (株)Ad生物技 | 通过抑制肠内胆固醇吸收而抑制高脂血症和肥胖症的组合物 |
| CN101935319A (zh) * | 2010-09-09 | 2011-01-05 | 陕西科技大学 | 一种黄连素有机酸盐和黄连素有机酸盐包合物及其制备方法 |
| CN102078418B (zh) | 2011-01-14 | 2012-04-18 | 广东药学院 | 一种防治脂代谢紊乱的复方中药提取物及其制备方法 |
| CN102225961A (zh) | 2011-04-21 | 2011-10-26 | 东北林业大学 | 小檗碱9位偶合胆酸新衍生物及其制备方法 |
| CN102370643A (zh) | 2011-07-20 | 2012-03-14 | 吉林敖东集团大连药业股份有限公司 | 盐酸小檗碱药物组合物及其制备方法 |
| JP2014530816A (ja) * | 2011-10-14 | 2014-11-20 | ノバルティスアーゲー | Ｗｎｔ経路関連疾患のための抗体および方法 |
| CN102580087B (zh) * | 2012-03-08 | 2013-08-21 | 董萍 | 一种可用于人体局部减肥和美体的原位脂肪细胞系复合抑制剂及其制备方法 |
| CN103319479B (zh) * | 2012-03-20 | 2015-08-26 | 王从品 | 大黄酸小檗碱离子对化合物、制备方法及应用 |
| US8652518B2 (en) | 2012-04-15 | 2014-02-18 | Jahahreeh Finley | Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation |
| CN102702190B (zh) * | 2012-07-02 | 2016-04-27 | 东北制药集团股份有限公司 | 一种小檗碱静电复合物及其制备方法 |
| JP2015533483A (ja) * | 2012-09-07 | 2015-11-26 | サノフイ | メタボリックシンドロームを治療するための融合タンパク質 |
| WO2014183184A1 (en) | 2013-05-14 | 2014-11-20 | University Of Prince Edward Island | Compositions and methods for treating cardiometabolic diseases and disorders |
| CN103989677A (zh) | 2013-12-20 | 2014-08-20 | 中国药科大学 | 去亚甲基小檗碱在制备降血糖药物中的应用 |
| US20150284406A1 (en) * | 2014-04-04 | 2015-10-08 | North American Biomedical Research Center Usa, Inc | Berberine-ursodeoxycholic acid conjugate for treating the liver |
| WO2015183794A1 (en) * | 2014-05-27 | 2015-12-03 | City Of Hope | Tgr5 agonist complexes for treating diabetes and cancer |
| NZ728488A (en) * | 2014-07-29 | 2023-03-31 | Shenzhen Hightide Biopharmaceutical Ltd | Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof |
-
2015
- 2015-07-28 NZ NZ728488A patent/NZ728488A/en unknown
- 2015-07-28 IL IL294063A patent/IL294063B2/en unknown
- 2015-07-28 KR KR1020177004835A patent/KR102573865B1/ko active Active
- 2015-07-28 JP JP2016564633A patent/JP6917144B2/ja active Active
- 2015-07-28 CA CA2945609A patent/CA2945609C/en active Active
- 2015-07-28 EP EP15826295.6A patent/EP3174874B1/en active Active
- 2015-07-28 IL IL282156A patent/IL282156B/en unknown
- 2015-07-28 WO PCT/CN2015/085350 patent/WO2016015634A1/en not_active Ceased
- 2015-07-28 ES ES15826295T patent/ES2835874T3/es active Active
- 2015-07-28 SG SG11201700481YA patent/SG11201700481YA/en unknown
- 2015-07-28 EA EA201790124A patent/EA032971B1/ru not_active IP Right Cessation
- 2015-07-28 KR KR1020237029438A patent/KR20230134598A/ko not_active Ceased
- 2015-07-28 BR BR112017001623-0A patent/BR112017001623B1/pt active IP Right Grant
- 2015-07-28 MX MX2017001372A patent/MX373840B/es active IP Right Grant
- 2015-07-28 CN CN201580041177.9A patent/CN106687460B/zh active Active
- 2015-07-28 CA CA3194562A patent/CA3194562A1/en active Pending
- 2015-07-28 US US15/303,468 patent/US10301303B2/en active Active
- 2015-07-28 CN CN201910386683.1A patent/CN110179792A/zh active Pending
- 2015-07-28 DK DK15826295.6T patent/DK3174874T3/da active
- 2015-07-28 AU AU2015296098A patent/AU2015296098B2/en active Active
- 2015-07-28 KR KR1020247042512A patent/KR20250008786A/ko active Pending
-
2017
- 2017-01-26 IL IL250317A patent/IL250317B/en active IP Right Grant
- 2017-01-30 MX MX2019013426A patent/MX2019013426A/es unknown
- 2017-01-30 MX MX2022009595A patent/MX2022009595A/es unknown
-
2019
- 2019-03-13 US US16/351,819 patent/US10988471B2/en active Active
- 2019-08-29 AU AU2019222911A patent/AU2019222911B2/en active Active
- 2019-12-27 JP JP2019237753A patent/JP2020073546A/ja active Pending
-
2021
- 2021-03-17 US US17/204,776 patent/US11685735B2/en active Active
- 2021-11-25 JP JP2021190958A patent/JP7285903B2/ja active Active
-
2023
- 2023-02-21 US US18/112,329 patent/US11976063B2/en active Active
- 2023-05-23 JP JP2023084632A patent/JP2023099689A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020073546A5 (enExample) | ||
| AU2019222911A1 (en) | Berberine salts, ursodeoxycholic salts and combinations, methods of prepration and application thereof | |
| JP2017522264A5 (enExample) | ||
| JP2018514534A5 (enExample) | ||
| JP2023002662A5 (enExample) | ||
| AU2019334939B2 (en) | Combination therapy for the treatment of liver disease | |
| JP2014515373A5 (enExample) | ||
| JP2009530413A5 (enExample) | ||
| RU2011139643A (ru) | Способ лечения неалкогольного стеатогепатита повышенными дозами урсодезоксихолевой кислоты | |
| JP2013509411A5 (enExample) | ||
| JP2018513188A5 (enExample) | ||
| ME02474B (me) | Terapijski režimi | |
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| CN107530309A (zh) | 共晶组合物及其药物用途 | |
| MX2024006271A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2016505050A5 (enExample) | ||
| TW201811372A (zh) | 利用fxr促效劑之方法 | |
| RU2019110779A (ru) | Новые схемы введения агонистов fxr | |
| CN101654393A (zh) | 作为肝脏保护剂的化合物和组合物 | |
| JP2019507786A5 (enExample) | ||
| JPWO2020257671A5 (enExample) | ||
| WO2001012214A3 (en) | MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) | |
| MX2024006270A (es) | Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2019513706A5 (enExample) | ||
| JPH08291077A (ja) | 骨萎縮改善剤 |